Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

BuSpar Generic Decision Favors Bristol: FDA Decision On ANDAs Pending

Related Content

Bristol BuSpar Pediatric Labeling May Delay Second Round Of Generics

Oct 01 2001

BuSpar Appeal: Bristol Argues Mylan Evaded Waxman/Hatch By Filing Suit

Jul 16 2001

FTC Asks FDA To Clarify "Orange Book" Listing Criteria In Citizen Petition

May 28 2001

More from Archive

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window